title: Hemisphere Asymmetry of Response to Pharmacologic Treatment in an Alzheimer's Disease Mouse Model.
abstract: The aim of this study was to examine hemisphere asymmetry of response to pharmacologic treatment in an Alzheimer's disease mouse model using cilostazol as a chemical stimulus. Eight-month-old mice were assigned to vehicle or cilostazol treatment for three months and hemispheres were analyzed using quantitative proteomics. Bioinformatics interpretation showed that following treatment, aggregation of blood platelets significantly decreased in the right hemisphere whereas neurodegeneration significantly decreased and synaptic transmission increased in the left hemisphere only. Our study provides novel evidence on cerebral laterality of pharmacologic activity, with important implications in deciphering regional pharmacodynamic effects of existing drugs thus uncovering novel hemisphere-specific therapeutic targets.
authors.affiliation: Institute for Life Sciences, University of Southampton, UK.|Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, UK.
authors.forename: Antigoni
authors.initials: A
authors.lastname: Manousopoulou
authors.affiliation: Department of Regenerative Medicine and Tissue Engineering, National Cerebral and Cardiovascular Center, Japan.
authors.forename: Satoshi
authors.initials: S
authors.lastname: Saito
authors.affiliation: Department of Regenerative Medicine and Tissue Engineering, National Cerebral and Cardiovascular Center, Japan.
authors.forename: Yumi
authors.initials: Y
authors.lastname: Yamamoto
authors.affiliation: Biomarkers Research Program, Department of Biochemistry College of Science, King Saud University, KSA.|Prince Mutaib Chair for Biomarkers of Osteoporosis, Department of Biochemistry King Saud University, KSA.
authors.forename: Nasser M
authors.initials: NM
authors.lastname: Al-Daghri
authors.affiliation: Department of Neurology, National Cerebral and Cardiovascular Center, Japan.
authors.forename: Masafumi
authors.initials: M
authors.lastname: Ihara
authors.affiliation: Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, UK.
authors.forename: Roxana O
authors.initials: RO
authors.lastname: Carare
authors.affiliation: Institute for Life Sciences, University of Southampton, UK.|Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, UK.|Cancer Sciences, Faculty of Medicine, University of Southampton, UK.
authors.forename: Spiros D
authors.initials: SD
authors.lastname: Garbis
mesh_terms: D000544:Alzheimer Disease / Q000188:drug therapy* / Q000378:metabolism*; D000818:Animals; D001921:Brain / Q000187:drug effects* / Q000378:metabolism*; D000077407:Cilostazol; D004195:Disease Models, Animal; D007839:Functional Laterality / Q000187:drug effects; D008297:Male; D008822:Mice, Transgenic; D018697:Nootropic Agents / Q000493:pharmacokinetics / Q000494:pharmacology*; D020543:Proteome / Q000187:drug effects; D013777:Tetrazoles / Q000493:pharmacokinetics / Q000494:pharmacology*
chemical_list: D018697:Nootropic Agents; D020543:Proteome; D013777:Tetrazoles; D000077407:Cilostazol
keywords: Alzheimer’s disease; cilostazol; hemisphere asymmetry; mass spectrometry pharmacology; pharmacodynamics; pharmacoproteomics
references.citation: Int J Obes (Lond). 2015 Aug;39(8):1325-8
references.pmid: 25797609
references.citation: Cortex. 2015 Jun;67:30-6
references.pmid: 25863470
references.citation: Drug Discov Today. 2010 Dec;15(23-24):1015-23
references.pmid: 20969973
references.citation: Cell Signal. 2014 Sep;26(9):2040-50
references.pmid: 24928203
references.citation: J Proteome Res. 2013 May 3;12(5):2078-89
references.pmid: 23510160
references.citation: Brain. 2006 Nov;129(Pt 11):2885-93
references.pmid: 17008332
references.citation: Brain Res. 2008 Apr 8;1203:170-6
references.pmid: 18321473
references.citation: Ann Clin Transl Neurol. 2014 Aug;1(8):519-33
references.pmid: 25356424
references.citation: Nat Rev Neurosci. 2006 Aug;7(8):655-62
references.pmid: 16858393
references.citation: Oncogene. 2014 Dec 11;33(50):5675-87
references.pmid: 24317512
references.citation: Nat Rev Neurosci. 2003 Jan;4(1):37-48
references.pmid: 12511860
references.citation: BMC Neurol. 2014 Dec 20;14:251
references.pmid: 25527141
references.citation: Stroke. 2011 Sep;42(9):2571-7
references.pmid: 21799161
references.citation: J Proteome Res. 2013 Apr 5;12 (4):1591-603
references.pmid: 23418717
references.citation: Curr Neurovasc Res. 2015;12(1):4-14
references.pmid: 25557380
references.citation: Biochem J. 2002 Jul 15;365(Pt 2):329-36
references.pmid: 12006104
references.citation: Neuroreport. 2002 Oct 28;13(15):1939-43
references.pmid: 12395096
references.citation: Antiviral Res. 2015 Nov;123:78-85
references.pmid: 26343910
references.citation: J Neurosci. 2003 Feb 1;23(3):994-1005
references.pmid: 12574429
references.citation: J Neurosci. 2013 Jan 30;33(5):2147-55
references.pmid: 23365250
references.citation: J Cereb Blood Flow Metab. 2010 Feb;30(2):299-310
references.pmid: 19826432
references.citation: PLoS One. 2014 Feb 26;9(2):e89516
references.pmid: 24586841
references.citation: Lancet Neurol. 2010 Oct;9(10):959-68
references.pmid: 20833591